Breaking Finance News

AstraZeneca PLC (LON:AZN) has been reiterated to Hold in a statement by Shore Capital earlier today.

Shore Capital has reiterated AstraZeneca PLC (LON:AZN) to Hold in a statement released on 9/14/2017.

On Wednesday September 13, 2017, Societe Generale released a statement for AstraZeneca PLC (LON:AZN) maintained the target price at 7,600.00GBX that suggested an upside of 0.58%.

Boasting a price of 4,861.25GBX, AstraZeneca PLC (LON:AZN) traded -1.61% lower on the day. With the last stock price close down -0.75% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. AstraZeneca PLC has recorded a 50-day average of 4,574.38GBX and a two hundred day average of 4,882.27GBX. Volume of trade was up over the average, with 2,352,977 shares of AZN changing hands over the typical 2,257,290

Performance Chart

AstraZeneca PLC (LON:AZN)

With a market cap of 0 GBX, AstraZeneca PLC has 52 week low of 3,996.00GBX and a 52 week high of 5,520.00GBX with a P/E ratio of 15.89 .

In addition to Shore Capital reporting its target price, a total of 29 firms have reported on the stock. The consensus target price is 61.96GBX with 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.

About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.